Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Camlipixant with Gemfibrozil or Dabigatran
NCT05959447Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of camlipixant in chronic cough (2 arms), sponsored by GSK. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity at Day 9, Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration at Day 9 and 1 more. Started Jul 2023; status: completed.
02
Drugs
camlipixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT05959447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959447.